Psoriatic Arthritis | Treatment Algorithms: Claims Data Analysis | US | 2017
The algorithms for treating psoriatic arthritis ( PsA ) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same therapies that are frequently used for PsA . Therefore, biologic and targeted synthetic DMARD s are more frequently used as early-line therapies after the diagnosis of PsA . Understanding the use of non- TNF inhibitors, namely, IL -12/23 inhibitors, IL -17 inhibitors, and PDE -4 inhibitors, is crucial for pharmaceutical companies to properly manage their brands in the PsA market. Claims data analysis provides an objective lens to see how physicians prescribe therapies and reveals real-world data on persistency and compliance of the PsA therapies.
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
